{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:23:20Z","timestamp":1791822200688,"version":"4.3.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,13]]},"DOI":"10.7759\/cureus.77370","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:12:07Z","timestamp":1736777527000},"source":"Crossref","is-referenced-by-count":4,"title":["The Pharmacological and Clinical Roles of Antiemetics: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Alan D","family":"Kaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donovan B","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex V","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibin","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801238-3.10923-7","article-title":"Pathophysiological mechanisms of gastrointestinal toxicity","author":"Gelberg H","year":"2017","unstructured":"Gelberg H. Pathophysiological mechanisms of gastrointestinal toxicity. Comprehensive Toxicology. 2017, 139-78. 10.1016\/B978-0-12-801238-3.10923-7","journal-title":"Comprehensive Toxicology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2016.09.013","article-title":"Fluid and electrolyte therapy during vomiting and diarrhea","volume":"47","author":"Tello L","year":"2017","unstructured":"Tello L, Perez-Freytes R. Fluid and electrolyte therapy during vomiting and diarrhea. Vet Clin North Am Small Anim Pract. 2017, 47:505-19. 10.1016\/j.cvsm.2016.09.013","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref3","article-title":"Electrolyte disorders and arrhythmogenesis","volume":"18","author":"El-Sherif N","year":"2011","unstructured":"El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011, 18:233-45.","journal-title":"Cardiol J"},{"key":"ref4","article-title":"Antiemetic neurokinin-1 receptor blockers","author":"Ibrahim MA","year":"2024","unstructured":"Ibrahim MA, Pellegrini MV, Preuss CV. Antiemetic neurokinin-1 receptor blockers. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199504000-00017","article-title":"Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial","volume":"18","author":"Malik IA","year":"1995","unstructured":"Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995, 18:170-5. 10.1097\/00000421-199504000-00017","journal-title":"Am J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2020.011","article-title":"Antiemetic drugs: what to prescribe and when","volume":"43","author":"Athavale A","year":"2020","unstructured":"Athavale A, Athavale T, Roberts DM. Antiemetic drugs: what to prescribe and when. Aust Prescr. 2020, 43:49-56. 10.18773\/austprescr.2020.011","journal-title":"Aust Prescr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115797","article-title":"Mechanisms of nausea and vomiting: current knowledge and recent advances in intracellular emetic signaling systems","volume":"22","author":"Zhong W","year":"2021","unstructured":"Zhong W, Shahbaz O, Teskey G, Beever A, Kachour N, Venketaraman V, Darmani NA. Mechanisms of nausea and vomiting: current knowledge and recent advances in intracellular emetic signaling systems. Int J Mol Sci. 2021, 22:5797. 10.3390\/ijms22115797","journal-title":"Int J Mol Sci"},{"key":"ref8","article-title":"Intestinal obstruction: evaluation and management","volume":"98","author":"Jackson P","year":"2018","unstructured":"Jackson P, Vigiola Cruz M. Intestinal obstruction: evaluation and management. Am Fam Physician. 2018, 98:362-7.","journal-title":"Am Fam Physician"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-34076-0_8","article-title":"Nausea and vomiting related to the central nervous system diseases","author":"Kuo B","year":"2017","unstructured":"Kuo B, Singh P. Nausea and vomiting related to the central nervous system diseases. Nausea and vomiting. Koch K, Hasler W (ed): Springer, Cham, Switzerland; 2017. 109-18. 10.1007\/978-3-319-34076-0_8"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.10.030","article-title":"A practical 5-step approach to nausea and vomiting","volume":"97","author":"Tome J","year":"2022","unstructured":"Tome J, Kamboj AK, Sweetser S. A practical 5-step approach to nausea and vomiting. Mayo Clin Proc. 2022, 97:600-8. 10.1016\/j.mayocp.2021.10.030","journal-title":"Mayo Clin Proc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta K","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021, 26:100278. 10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh PJ","year":"2008","unstructured":"Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008, 358:2482-94. 10.1056\/NEJMra0706547","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s44231-023-00054-3","article-title":"Correction of electrolyte abnormalities in critically Ill patients","volume":"4","author":"Bulloch MN","year":"2024","unstructured":"Bulloch MN, Cardinale-King M, Cogle S, Radparvar S, Effendi M, Jagpal S, Dixit D. Correction of electrolyte abnormalities in critically Ill patients. Intensive Care Res. 2024, 4:19-37. 10.1007\/s44231-023-00054-3","journal-title":"Intensive Care Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06997-5","article-title":"Pain, fatigue, nausea, and vomiting as the predictors of anxiety in patients undergoing hematopoietic stem cell transplantation: a prospective cohort study","volume":"30","author":"Pasyar N","year":"2022","unstructured":"Pasyar N, Rambod M, Zahedi F, Ramzi M. Pain, fatigue, nausea, and vomiting as the predictors of anxiety in patients undergoing hematopoietic stem cell transplantation: a prospective cohort study. Support Care Cancer. 2022, 30:5871-9. 10.1007\/s00520-022-06997-5","journal-title":"Support Care Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2011.03.009","article-title":"Nausea and vomiting of pregnancy","volume":"40","author":"Lee NM","year":"2011","unstructured":"Lee NM, Saha S. Nausea and vomiting of pregnancy. Gastroenterol Clin North Am. 2011, 40:309-34. 10.1016\/j.gtc.2011.03.009","journal-title":"Gastroenterol Clin North Am"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-536x.1995.tb00566.x","article-title":"Variables related to nausea and vomiting during pregnancy","volume":"22","author":"O'Brien B","year":"1995","unstructured":"O'Brien B, Zhou Q. Variables related to nausea and vomiting during pregnancy. Birth. 1995, 22:93-100. 10.1111\/j.1523-536x.1995.tb00566.x","journal-title":"Birth"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002604","article-title":"ACOG practice bulletin 189: nausea and vomiting of pregnancy","volume":"131","author":"Erick M","year":"2018","unstructured":"Erick M, Cox JT, Mogensen KM. ACOG practice bulletin 189: nausea and vomiting of pregnancy. Obstet Gynecol. 2018, 131:935. 10.1097\/AOG.0000000000002604","journal-title":"Obstet Gynecol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0000206336.08794.65","article-title":"Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature","volume":"61","author":"Chiossi G","year":"2006","unstructured":"Chiossi G, Neri I, Cavazzuti M, Basso G, Facchinetti F. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet Gynecol Surv. 2006, 61:255-68. 10.1097\/01.ogx.0000206336.08794.65","journal-title":"Obstet Gynecol Surv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21767\/2471-8165.1000025","article-title":"Why are women still dying from nausea and vomiting of pregnancy?","volume":"2","author":"Fejzo MS","year":"2016","unstructured":"Fejzo MS, MacGibbon K, Mullin PM. Why are women still dying from nausea and vomiting of pregnancy?. Gynecol Obstet Case Rep. 2016, 2:2. 10.21767\/2471-8165.1000025","journal-title":"Gynecol Obstet Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yhbeh.2023.105360","article-title":"Associations between nausea and vomiting in pregnancy, disgust sensitivity, and first-trimester maternal serum free \u03b2-hCG and PAPP-A","volume":"152","author":"Ka\u0148kov\u00e1 \u0160","year":"2023","unstructured":"Ka\u0148kov\u00e1 \u0160, Hlav\u00e1\u010dov\u00e1 J, Roberts K, et al.. Associations between nausea and vomiting in pregnancy, disgust sensitivity, and first-trimester maternal serum free \u03b2-hCG and PAPP-A. Horm Behav. 2023, 152:105360. 10.1016\/j.yhbeh.2023.105360","journal-title":"Horm Behav"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06921-9","article-title":"GDF15 linked to maternal risk of nausea and vomiting during pregnancy","volume":"625","author":"Fejzo M","year":"2024","unstructured":"Fejzo M, Rocha N, Cimino I, et al.. GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Nature. 2024, 625:760-7. 10.1038\/s41586-023-06921-9","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(87)90126-8","article-title":"Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study","volume":"156","author":"Depue RH","year":"1987","unstructured":"Depue RH, Bernstein L, Ross RK, Judd HL, Henderson BE. Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. Am J Obstet Gynecol. 1987, 156:1137-41. 10.1016\/0002-9378(87)90126-8","journal-title":"Am J Obstet Gynecol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12468","article-title":"Motion sickness: current knowledge and recent advance","volume":"22","author":"Zhang LL","year":"2016","unstructured":"Zhang LL, Wang JQ, Qi RR, Pan LL, Li M, Cai YL. Motion sickness: current knowledge and recent advance. CNS Neurosci Ther. 2016, 22:15-24. 10.1111\/cns.12468","journal-title":"CNS Neurosci Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2224-5820.2012.07.07","article-title":"5-HT3 receptor antagonists for the treatment of nausea\/vomiting","volume":"1","author":"Smith HS","year":"2012","unstructured":"Smith HS, Cox LR, Smith EJ. 5-HT3 receptor antagonists for the treatment of nausea\/vomiting. Ann Palliat Med. 2012, 1:115-20. 10.3978\/j.issn.2224-5820.2012.07.07","journal-title":"Ann Palliat Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001485","article-title":"Nausea and vomiting in 2021: a comprehensive update","volume":"55","author":"Heckroth M","year":"2021","unstructured":"Heckroth M, Luckett RT, Moser C, Parajuli D, Abell TL. Nausea and vomiting in 2021: a comprehensive update. J Clin Gastroenterol. 2021, 55:279-99. 10.1097\/MCG.0000000000001485","journal-title":"J Clin Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000163","article-title":"Pathophysiology and treatment of motion sickness","volume":"28","author":"Golding JF","year":"2015","unstructured":"Golding JF, Gresty MA. Pathophysiology and treatment of motion sickness. Curr Opin Neurol. 2015, 28:83-8. 10.1097\/WCO.0000000000000163","journal-title":"Curr Opin Neurol"},{"key":"ref27","doi-asserted-by":"crossref","DOI":"10.1080\/00016489.1985.12005655","article-title":"Experimental vestibular pharmacology: a minireview with special reference to neuroactive substances and antivertigo drugs","volume":"98","author":"Matsuoka I","year":"1985","unstructured":"Matsuoka I, Ito J, Takahashi H, Sasa M, Takaori S. Experimental vestibular pharmacology: a minireview with special reference to neuroactive substances and antivertigo drugs. Acta Oto-Laryngol. 1985, 98:62-70.","journal-title":"Acta Oto-Laryngol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5250","article-title":"Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial","volume":"4","author":"Wang DS","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, et al.. Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open. 2021, 4:e215250. 10.1001\/jamanetworkopen.2021.5250","journal-title":"JAMA Netw Open"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31826f0a0a","article-title":"Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials","volume":"116","author":"De Oliveira GS Jr","year":"2013","unstructured":"De Oliveira GS Jr, Castro-Alves LJ, Ahmad S, Kendall MC, McCarthy RJ. Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials. Anesth Analg. 2013, 116:58-74. 10.1213\/ANE.0b013e31826f0a0a","journal-title":"Anesth Analg"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1455","article-title":"Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial)","volume":"357","author":"DREAMS Trial Collaborators and West Midlands Research Collaborative","year":"2017","unstructured":"DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ. 2017, 357:j1455. 10.1136\/bmj.j1455","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1394549","article-title":"Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice","volume":"19","author":"Wong J","year":"2018","unstructured":"Wong J, Tran LT, Lynch KA, Wood LJ. Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice. Cancer Biol Ther. 2018, 19:87-96. 10.1080\/15384047.2017.1394549","journal-title":"Cancer Biol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1384","article-title":"Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam","volume":"11","author":"Razavi D","year":"1993","unstructured":"Razavi D, Delvaux N, Farvacques C, et al.. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol. 1993, 11:1384-90. 10.1200\/JCO.1993.11.7.1384","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-50909-9_12-1","article-title":"Understanding the routes of administration","author":"Gupta D","year":"2019","unstructured":"Gupta D, Gupta SV, Yang N. Understanding the routes of administration. Handbook of space pharmaceuticals. Pathak Y, Ara\u00fajo dos Santos M, Zea L (ed): Springer, Cham, Switzerland; 2019. 1-25. 10.1007\/978-3-319-50909-9_12-1"},{"key":"ref34","article-title":"End-of-life care: managing common symptoms","volume":"95","author":"Albert RH","year":"2017","unstructured":"Albert RH. End-of-life care: managing common symptoms. Am Fam Physician. 2017, 95:356-61.","journal-title":"Am Fam Physician"},{"key":"ref35","article-title":"Practical selection of antiemetics","volume":"69","author":"Flake ZA","year":"2004","unstructured":"Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician. 2004, 69:1169-74.","journal-title":"Am Fam Physician"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28248038","article-title":"The bioavailability of drugs-the current state of knowledge","volume":"28","author":"Stielow M","year":"2023","unstructured":"Stielow M, Witczy\u0144ska A, Kubry\u0144 N, Fija\u0142kowski \u0141, Nowaczyk J, Nowaczyk A. The bioavailability of drugs-the current state of knowledge. Molecules. 2023, 28:8038. 10.3390\/molecules28248038","journal-title":"Molecules"},{"key":"ref37","article-title":"Evidence for the use of intramuscular injections in outpatient practice","volume":"79","author":"Shatsky ML","year":"2009","unstructured":"Shatsky ML. Evidence for the use of intramuscular injections in outpatient practice. Am Fam Physician. 2009, 79:297-300.","journal-title":"Am Fam Physician"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122312","article-title":"Delivery of biologics: topical administration","volume":"302","author":"Kulchar RJ","year":"2023","unstructured":"Kulchar RJ, Singh R, Ding S, Alexander E, Leong KW, Daniell H. Delivery of biologics: topical administration. Biomaterials. 2023, 302:122312. 10.1016\/j.biomaterials.2023.122312","journal-title":"Biomaterials"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2224-5820.2012.07.09","article-title":"Dopamine receptor antagonists","volume":"1","author":"Smith HS","year":"2012","unstructured":"Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliat Med. 2012, 1:137-42. 10.3978\/j.issn.2224-5820.2012.07.09","journal-title":"Ann Palliat Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01196","article-title":"Physiological and pharmaceutical considerations for rectal drug formulations","volume":"10","author":"Hua S","year":"2019","unstructured":"Hua S. Physiological and pharmaceutical considerations for rectal drug formulations. Front Pharmacol. 2019, 10:1196. 10.3389\/fphar.2019.01196","journal-title":"Front Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2011.07.019","article-title":"Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting","volume":"24","author":"Pergolizzi JV Jr","year":"2012","unstructured":"Pergolizzi JV Jr, Philip BK, Leslie JB, Taylor R Jr, Raffa RB. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. J Clin Anesth. 2012, 24:334-45. 10.1016\/j.jclinane.2011.07.019","journal-title":"J Clin Anesth"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2165\/11202780-000000000-00000","article-title":"Transdermal granisetron","volume":"69","author":"Duggan ST","year":"2009","unstructured":"Duggan ST, Curran MP. Transdermal granisetron. Drugs. 2009, 69:2597-605. 10.2165\/11202780-000000000-00000","journal-title":"Drugs"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1053\/clon.1999.9077","article-title":"Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment","volume":"11","author":"LeBourgeois JP","year":"1999","unstructured":"LeBourgeois JP, McKenna CJ, Coster B, et al.. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. Clin Oncol (R Coll Radiol). 1999, 11:340-7. 10.1053\/clon.1999.9077","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jons.2018.07.003","article-title":"Drug-drug interactions between antiemetics used in cancer patients","volume":"4","author":"Umar RM","year":"2018","unstructured":"Umar RM. Drug-drug interactions between antiemetics used in cancer patients. J Oncol Sci. 2018, 4:142-6. 10.1016\/j.jons.2018.07.003","journal-title":"J Oncol Sci"},{"key":"ref45","article-title":"Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans","volume":"23","author":"Dixon CM","year":"1995","unstructured":"Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995, 23:1225-30.","journal-title":"Drug Metab Dispos"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2016.03.008","article-title":"Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine","volume":"14","author":"Ahmed S","year":"2016","unstructured":"Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinformatics. 2016, 14:298-313. 10.1016\/j.gpb.2016.03.008","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S136341","article-title":"CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications","volume":"10","author":"St Sauver JL","year":"2017","unstructured":"St Sauver JL, Olson JE, Roger VL, et al.. CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. Pharmgenomics Pers Med. 2017, 10:217-27. 10.2147\/PGPM.S136341","journal-title":"Pharmgenomics Pers Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00931","article-title":"Metoclopramide-induced acute dystonic reactions may be associated with the CYP2D6 poor metabolizer status and pregnancy-related hormonal changes","volume":"10","author":"Chua EW","year":"2019","unstructured":"Chua EW, Harger SP, Kennedy MA. Metoclopramide-induced acute dystonic reactions may be associated with the CYP2D6 poor metabolizer status and pregnancy-related hormonal changes. Front Pharmacol. 2019, 10:931. 10.3389\/fphar.2019.00931","journal-title":"Front Pharmacol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00055","article-title":"The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting","volume":"5","author":"Antor MA","year":"2014","unstructured":"Antor MA, Uribe AA, Erminy-Falcon N, Werner JG, Candiotti KA, Pergolizzi JV, Bergese SD. The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting. Front Pharmacol. 2014, 5:55. 10.3389\/fphar.2014.00055","journal-title":"Front Pharmacol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04190.x","article-title":"Pharmacokinetics of ondansetron in patients with hepatic insufficiency","volume":"36","author":"Figg WD","year":"1996","unstructured":"Figg WD, Dukes GE, Pritchard JF, et al.. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol. 1996, 36:206-15. 10.1002\/j.1552-4604.1996.tb04190.x","journal-title":"J Clin Pharmacol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2019.054","article-title":"How to adjust drug doses in chronic kidney disease","volume":"42","author":"Stefani M","year":"2019","unstructured":"Stefani M, Singer RF, Roberts DM. How to adjust drug doses in chronic kidney disease. Aust Prescr. 2019, 42:163-7. 10.18773\/austprescr.2019.054","journal-title":"Aust Prescr"},{"key":"ref52","article-title":"Antihistamines","author":"Farzam K","year":"2024","unstructured":"Farzam K, Sabir S, O'Rourke MC. Antihistamines. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref53","article-title":"Cimetidine","author":"Pino MA","year":"2024","unstructured":"Pino MA, Azer SA. Cimetidine. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref54","article-title":"Antiemetics, selective 5-HT3 antagonists","author":"Theriot J","year":"2024","unstructured":"Theriot J, Wermuth HR, Ashurst JV. Antiemetics, selective 5-HT3 antagonists. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref55","article-title":"[Comparative experimental study of antiemetic action of latranum in radiation-induced vomiting and vomiting caused by apomorphine] (Article in Russian)","volume":"43","author":"Martirosov KS","year":"2003","unstructured":"Martirosov KS, Grigor'ev IuG, Zorin VV, Borovkov MV. [Comparative experimental study of antiemetic action of latranum in radiation-induced vomiting and vomiting caused by apomorphine] (Article in Russian). Radiats Biol Radioecol. 2003, 43:60-4.","journal-title":"Radiats Biol Radioecol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.08.010","article-title":"Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection","volume":"20","author":"Hauser RA","year":"2014","unstructured":"Hauser RA, Isaacson S, Clinch T. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014, 20:1171-6. 10.1016\/j.parkreldis.2014.08.010","journal-title":"Parkinsonism Relat Disord"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-014-0004-3","article-title":"Can 5-HT(3) antagonists really contribute to serotonin toxicity? A call for clarity and pharmacological law and order","volume":"1","author":"Rojas-Fernandez CH","year":"2014","unstructured":"Rojas-Fernandez CH. Can 5-HT(3) antagonists really contribute to serotonin toxicity? A call for clarity and pharmacological law and order. Drugs Real World Outcomes. 2014, 1:3-5. 10.1007\/s40801-014-0004-3","journal-title":"Drugs Real World Outcomes"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.10.008","article-title":"The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting","volume":"722","author":"Chu CC","year":"2014","unstructured":"Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol. 2014, 722:48-54. 10.1016\/j.ejphar.2013.10.008","journal-title":"Eur J Pharmacol"},{"key":"ref59","article-title":"Antiemetic medications","author":"Hauser JM","year":"2024","unstructured":"Hauser JM, Azzam JS, Kasi\u00a0A. Antiemetic medications. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04189.x","article-title":"Review article: metoclopramide and tardive dyskinesia","volume":"31","author":"Rao AS","year":"2010","unstructured":"Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010, 31:11-9. 10.1111\/j.1365-2036.2009.04189.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref61","article-title":"Anticholinergic medications","author":"Ghossein N","year":"2024","unstructured":"Ghossein N, Kang M, Lakhkar AD. Anticholinergic medications. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs335","article-title":"Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review","volume":"104","author":"dos Santos LV","year":"2012","unstructured":"dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012, 104:1280-92. 10.1093\/jnci\/djs335","journal-title":"J Natl Cancer Inst"},{"key":"ref63","article-title":"Cannaboinoid antiemetic therapy","author":"Taylor BN","year":"2024","unstructured":"Taylor BN, Mueller M, Sauls RS. Cannaboinoid antiemetic therapy. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1089\/can.2018.0030","article-title":"Regulatory status of cannabidiol in the United States: a perspective","volume":"3","author":"Corroon J","year":"2018","unstructured":"Corroon J, Kight R. Regulatory status of cannabidiol in the United States: a perspective. Cannabis Cannabinoid Res. 2018, 3:190-4. 10.1089\/can.2018.0030","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S46653","article-title":"Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview","volume":"6","author":"Nuangchamnong N","year":"2014","unstructured":"Nuangchamnong N, Niebyl J. Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview. Int J Womens Health. 2014, 6:401-9. 10.2147\/IJWH.S46653","journal-title":"Int J Womens Health"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2344\/anpr-67-03-14","article-title":"The surprising re-emergence of droperidol","volume":"67","author":"Kramer KJ","year":"2020","unstructured":"Kramer KJ. The surprising re-emergence of droperidol. Anesth Prog. 2020, 67:125-6. 10.2344\/anpr-67-03-14","journal-title":"Anesth Prog"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060505","article-title":"Evidence-based review of the black-box warning for droperidol","volume":"64","author":"Jackson CW","year":"2007","unstructured":"Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm. 2007, 64:1174-86. 10.2146\/ajhp060505","journal-title":"Am J Health Syst Pharm"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.06.031","article-title":"The relationship between gastric motility and nausea: gastric prokinetic agents as treatments","volume":"715","author":"Sanger GJ","year":"2013","unstructured":"Sanger GJ, Broad J, Andrews PL. The relationship between gastric motility and nausea: gastric prokinetic agents as treatments. Eur J Pharmacol. 2013, 715:10-4. 10.1016\/j.ejphar.2013.06.031","journal-title":"Eur J Pharmacol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.86a.19005","article-title":"Beyond depression: other uses for tricyclic antidepressants","volume":"86","author":"Schneider J","year":"2019","unstructured":"Schneider J, Patterson M, Jimenez XF. Beyond depression: other uses for tricyclic antidepressants. Cleve Clin J Med. 2019, 86:807-14. 10.3949\/ccjm.86a.19005","journal-title":"Cleve Clin J Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1052","article-title":"Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial","volume":"6","author":"Navari RM","year":"2020","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL. Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial. JAMA Oncol. 2020, 6:895-9. 10.1001\/jamaoncol.2020.1052","journal-title":"JAMA Oncol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation working team report","volume":"154","author":"Drossman DA","year":"2018","unstructured":"Drossman DA, Tack J, Ford AC, Szigethy E, T\u00f6rnblom H, Van Oudenhove L. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation working team report. Gastroenterology. 2018, 154:1140-71.e1. 10.1053\/j.gastro.2017.11.279","journal-title":"Gastroenterology"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari RM","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, et al.. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016, 375:134-42. 10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.26076","article-title":"Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial","volume":"7","author":"Ostwal V","year":"2024","unstructured":"Ostwal V, Ramaswamy A, Mandavkar S, et al.. Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial. JAMA Netw Open. 2024, 7:e2426076. 10.1001\/jamanetworkopen.2024.26076","journal-title":"JAMA Netw Open"},{"key":"ref74","article-title":"Inhaled isopropyl alcohol for nausea and vomiting in the emergency department","volume":"64","author":"Lindblad AJ","year":"2018","unstructured":"Lindblad AJ, Ting R, Harris K. Inhaled isopropyl alcohol for nausea and vomiting in the emergency department. Can Fam Physician. 2018, 64:580.","journal-title":"Can Fam Physician"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/327306-the-pharmacological-and-clinical-roles-of-antiemetics-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:12:13Z","timestamp":1736777533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/327306-the-pharmacological-and-clinical-roles-of-antiemetics-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":74,"URL":"https:\/\/doi.org\/10.7759\/cureus.77370","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}